Welcome to our dedicated page for nyse news (Ticker: nyse), a resource for investors and traders seeking the latest updates and insights on nyse stock.
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) is a pioneering biopharmaceutical company focused on developing targeted radiotherapies for treating cancer. Founded with the mission of improving survival outcomes for patients with difficult-to-treat cancers, Actinium leverages its proprietary Antibody Radiation Conjugates (ARCs) to deliver potent radiation directly to cancer cells while sparing healthy tissue.
Actinium's leading candidates include Iomab-B and Actimab-A. Iomab-B is a radioimmunotherapy intended for conditioning before bone marrow transplants in patients with active relapsed or refractory acute myeloid leukemia (r/r AML). The pivotal Phase 3 SIERRA trial has demonstrated Iomab-B's ability to significantly improve overall survival and remission rates, particularly in patients with the high-risk TP53 mutation. Advanced filings for Biologics License Application (BLA) and Marketing Authorization Application (MAA) are underway.
Actimab-A, targeting CD33, is being developed as a therapeutic for r/r AML and is currently progressing under the National Cancer Institute’s CRADA pivotal development path. This candidate, along with Iomab-B, has shown promising results in overcoming genetic mutations and providing high response rates.
In addition to its robust pipeline, Actinium is actively involved in partnerships to extend its technology platform to solid tumors. Notable collaborations include those with Astellas Pharma, AVEO Oncology, and LG Chem Life Sciences. The company holds an extensive intellectual property portfolio with over 230 patents and patent applications.
Recent developments include the initiation of a clinical trial for Iomab-ACT, a next-generation conditioning agent for cell and gene therapies such as CAR T-cell therapy. This trial, led by the University of Texas Southwestern Medical Center, aims to replace traditional chemotherapy conditioning with targeted radiotherapy to reduce toxicities and improve patient outcomes.
Actinium’s strong presence at major scientific conferences such as the American Society of Hematology (ASH), European Bone Marrow Transplant Society (EBMT), and Tandem Meetings of ASTCT and CIBMTR underscores its commitment to advancing targeted radiotherapies and highlights the potential of its innovative treatments in transforming cancer care.
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) announced FDA clearance for an IND application to study Iomab-ACT for targeted conditioning prior to bone marrow transplant (BMT) in sickle cell disease patients. The study, in collaboration with Columbia University, aims to evaluate Iomab-ACT's safety and potentially inform future gene therapy conditioning trials. Iomab-ACT, an Antibody Radiation Conjugate targeting CD45, could replace current non-targeted chemotherapy and total body irradiation conditioning methods, potentially reducing severe side effects and broadening access to curative cellular therapies. This initiative addresses the high unmet need among approximately 100,000 U.S. sickle cell patients annually. The study aligns with Actinium's strategy to expand Iomab-ACT's applications in transplant, cell therapy, and gene therapy conditioning, tapping into a growing market for CAR-T and gene therapies expected to reach 93,000 U.S. patients by 2030.
Actinium Pharmaceuticals announced that the Phase 3 SIERRA trial results of Iomab-B will be presented at the EHA 2024 Congress. The trial demonstrated significant survival benefits in older patients with relapsed or refractory acute myeloid leukemia (r/r AML) receiving an Iomab-B led bone marrow transplant (BMT). Patients with TP53 mutations saw a median overall survival of 5.49 months compared to 1.66 months for those not receiving Iomab-B. The trial enrolled high-risk patients and showed 92% 1-year survival and 69% 2-year survival rates in those receiving Iomab-B led BMT.
Actinium Pharmaceuticals, Inc. announced a KOL webinar to discuss its Iomab-ACT trial with a leading FDA approved CAR T-cell therapy at the University of Texas Southwestern. The webinar will highlight the potential billion-dollar market opportunity in lymphodepletion. Dr. Farrukh Awan will lead the trial, aiming to study Iomab-ACT with an FDA approved CAR-T cell therapy for the first time. The company presented positive phase 1 trial results at the Tandem Meetings, showing promising safety and efficacy profiles. With the expanding CAR-T market and the need for improved conditioning in cellular therapy, Iomab-ACT presents a revenue opportunity in line with the growing patient population for cell and gene therapies.
FAQ
What is Actinium Pharmaceuticals' primary focus?
What is Iomab-B?
What recent achievements has Actinium Pharmaceuticals made?
Who are Actinium Pharmaceuticals' key partners?
What is Actimab-A?
What are the key results from the SIERRA trial?
What is the significance of Actinium's technology platform?
How many patents does Actinium Pharmaceuticals hold?
What is the purpose of Iomab-ACT?
Where can I find more information about Actinium Pharmaceuticals?
